Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Cipher Pharmaceuticals ( (TSE:CPH) ) has issued an update.
Cipher Pharmaceuticals reported significant financial growth in 2024, with total revenue increasing by 58% to $33.4 million, driven by the acquisition of Natroba and strong performance of Epuris. The acquisition of Natroba has provided Cipher with a U.S. commercial footprint, enhancing its growth strategy and cash flow generation, supported by a new credit facility with the National Bank of Canada.
More about Cipher Pharmaceuticals
Cipher Pharmaceuticals is a company in the pharmaceutical industry, focusing on dermatology and infectious disease products. Its primary products include Epuris, a leading product in Canada, and Natroba, which was recently acquired to expand its U.S. market presence.
YTD Price Performance: -19.63%
Average Trading Volume: 16,713
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $203.3M
Find detailed analytics on CPH stock on TipRanks’ Stock Analysis page.
Trending Articles:
- “The No. 1 Destination for the Most Talented Artists”: Netflix Stock (NASDAQ:NFLX) Notches Up as the Duffer Brothers Consider Jumping Ship
- “Breakthrough EVs”: Ford Stock (NYSE:F) Notches Up on New Battery Details
- “An Equity Stake”: Intel Stock (NASDAQ:INTC) Surges as U.S. Government May Buy In With CHIPS Act Money